Loading...
CORCEPT THERAPEUTICS INC's top 2 named executive officers received combined total compensation of $13.9 million in fiscal year 2024.
The named executive officers disclosed in CORCEPT THERAPEUTICS INC's 2024 proxy statement are:Joseph K. Belanoff (President) with total compensation of $9.9 million, and William Guyer (Chief Development Officer) with total compensation of $4.0 million.
President
71% equity · 29% cash
Based on DEF 14A filed 2025-04-25 · FY2024
Team view
2 executives
President
Total PayFY2024
$9.9M
Chief Development Officer
Total PayFY2024
$4.0M
FY2024 total compensation breakdown
$9.9M total compensation
Joseph K. Belanoff earned $9.9M in FY2024 — here's how that breaks down.
$7.0M
71% of total
$1.7M
17% of total
$1.1M
12% of total
$23.0K
0% of total
Activity timeline · FY2024
Recent events from filings
An AI summary will appear here once the pay verdict loads above.
Pay changes vs. stock performance
Recent insider trades by officers and directors
~100 trades
For analysts and deep research
Historical compensation data from latest proxy filing
| Year | Executive | Salary | Bonus & Incentive | Stock Awards | Option Awards | Other Adj. | Total |
|---|---|---|---|---|---|---|---|
| 2024 | Joseph K. Belanoff President | $1.14M | $1.72M | $0.00M | $7.01M | $0.02M | $9.89M |
| 2023 | Joseph K. Belanoff President | $1.08M | $1.32M | $0.00M | $6.91M | $0.02M | $9.34M |
| 2022 | Joseph K. Belanoff President | $0.90M | $0.90M | $0.00M | $5.54M | $0.02M | $7.35M |
Salary = base cash pay. Bonus & Incentive combines annual bonus and non-equity plans. Equity amounts are grant-date fair values. Other Adj. captures pension changes, perquisites, and any reconciliation items so the total matches the reported figure.
Get one email when new executive compensation data is filed and processed.